MFN — Lanton Law Blog

Lanton Law Speaks with Drug Topics on Its Over the Counter Podcast on MFN

Lanton Law speaks with Drug Topics on their podcast episode of Over the Counter. Ron discusses developing policy expected to enact significant change in the pharmacy industry and beyond titled “Most Favored Nation: Global Benchmarking to Reimagine US Drug Distribution.”

CMS, healthcare, HHS, drug priceRon LantonDecember 19, 2025MFN, drug prices, Most-Favored-Nation (MFN) Pricing, CMS, HHS, healthcare, pharmacy, PBM, insurance

Lanton Law Returns to Moderate Most Favored Nation Panel for Pharmacy Times

Lanton Law retuned to moderate the third and final panel on MFN for Pharmacy Times titled “How Trump Is Disrupting Pharma: Exploring the Impacts of MFN, Tariffs and DTC on Drug Markets.”

healthcare, life sciencesRon LantonNovember 25, 2025Most Favored Nation, MFN, drug pricing, healthcare, life sciences

Lanton Law Quoted in Bloomberg Law

We have been talking a lot lately about drug pricing; specifically Most Favored Nation (MFN) and other ancillary issues. We were recently quoted in Bloomberg Law News on the issue here.

life sciences, healthcareRon LantonNovember 25, 2025healthcare, MFN, Most-Favored-Nation (MFN) Pricing, drug pricing

Lanton Law Moderates Most Favored Nation Panel for MJH Life Sciences

Lanton Law was honored to be selected as a moderator for the MJH Life Sciences panel titled ““Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform.”

Lanton Law Interviewed by Pharmacy Times Over Prescription Drug Price Executive Order

Lanton Law was quoted in Pharmacy Times’ article titled “President Trump Signs Executive Order Aiming to Lower Prescription Drug Costs by Up to 90%.”